Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

Canadian Intellectual Property Office
An agency of Industry Canada

CA 2391076 C 2008/06/17

(11)(21) 2 391 076

(12) BREVET CANADIEN
CANADIAN PATENT

(13) C

(86) Date de dépôt PCT/PCT Filing Date: 2000/10/14
(87) Date publication PCT/PCT Publication Date: 2001/05/25
(45) Date de délivrance/Issue Date: 2008/06/17
(85) Entrée phase nationale/National Entry: 2002/05/10
(86) N° demande PCT/PCT Application No.: EP 2000/010122
(87) N° publication PCT/PCT Publication No.: 2001/035962
(30) Priorité/Priority: 1999/11/12 (DE199 54 516.2)

(51) Cl.Int./Int.Cl. *A61K 31/55* (2006.01), *A61K 9/08* (2006.01), *A61P 11/02* (2006.01), *A61P 37/08* (2006.01)

(72) Inventeurs/Inventors:
TRACH, VOLKER, DE;
DUSCHLER, GEROLD, DE

(73) Propriétaire/Owner:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : SOLUTIONS CONTENANT DE L'EPINASTINE
(54) Title: SOLUTIONS CONTAINING EPINASTIN

(57) Abrégé/Abstract:
The invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemate or its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.

Abstract

The invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemate or its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.

71741J.202

Case 1/1112-Prio-Dr.Wy BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Solutions containing epinastin

The invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemates, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.

Background of the Invention

Allergic reactions of the eye (hereinafter referred to as ocular allergic reactions) signifies a series of differently defined syndromes. The following are examples of ocular allergic reactions, e.g.: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant cell conjunctivitis, vernal keratoconjunctivitis or atopic keratoconjunctivitis. Examples of allergic reactions of the nose (hereinafter referred to as nasal allergic reactions) include seasonal allergic rhinitis and perennial allergic rhinitis, for example.

The immunological mechanism on which ocular and nasal allergic reactions are based comprises *inter alia* inflammatory processes caused by histamine. The allergic reactions produced by the release of histamine occur at an early stage of the ocular and nasal allergic reactions mentioned above.
Moreover, ocular and nasal allergic reactions may be due to the release of other mast cell mediators as well as toxic eosinophilic granule proteins and enzymes. The influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane leads to a late phase reaction, hereinafter referred to as LPR.

LPR normally occurs within a period of 3-6 hours after the initial histamine-mediated allergic reaction. LPR is also characterised by the occurrence of vasodilation and chemosis and by the swelling of the conjunctiva and the nasal mucous membrane.

Whereas histamine-produced allergic reactions can be counteracted by administering antihistamines, the influx of neurophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane remains unaffected by administering pure antihistamines.

Problem of the Invention

The problem of the present invention is therefore to provide topically administerable solutions which inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are therefore characterised by a longer lasting duration of activity.

According to one aspect of the present invention, there is provided use of a solution consisting of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative, in preparing a medicament for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

According to another aspect of the present invention, there is provided use of a solution consisting

of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative; and e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters, antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution, in preparing a medicament for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

According to still another aspect of the present invention, there is provided use of a solution consisting of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative, for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

According to yet another aspect of the present invention, there is provided use of a solution consisting of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative; and e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters,

antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution, for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

According to a further aspect of the present invention, there is provided a solution consisting of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative, for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

According to yet a further aspect of the present invention, there is provided a solution consisting of: a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%; b) water or a physiological saline solution as solvent; c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and d) a preservative; and e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters, antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution, for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

More Detailed Description of the Invention

It has been found, surprisingly, that topically administerable aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers and

possibly in the form of the pharmacologically acceptable acid addition salts thereof, may be used to solve the problem on which the invention is based, since they inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are accordingly characterised by a longer lasting duration of activity.

The compound epinastin (3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazol[1,5-a]azepine) and the acid addition salts

thereof are described for the first time in German Patent Application P 30 08 944.2.

The effect of the topically administered solutions containing epinastin as inhibitors of the influx of eosinophils and neutrophils was demonstrated using the so-called passive ocular anaphylaxis model in rats.

Description of Experiment:

72 hours after the rats have been sensitised by injecting antiserum into the eyelids of the test animals, a fresh provocation was induced in them by intravenous administration of ovalbumin. Some of the experimental animals were pretreated by the administration of solution containing epinastin according to the invention into the conjunctival sac 15 minutes before the ovalbumin is administered. Two hours after the administration of ovalbumin the experimental animals were killed and the conjunctiva was investigated for its content of eosinophils and neutrophils and the mast cell granulation was determined.

Results:

The animals pretreated with epinastin solution according to the invention (0.05-0.5%) had a significantly lower content of eosinophils in their conjunctiva. The animals pretreated with epinastin solution according to the invention had a significantly lower content of lymphocytes in their conjunctiva ($p<0.01$). In the animals pretreated with epinastin solution according to the invention, a roughly 35% inhibition of mast cell degranulation was determined ($p<0.01$).

Consequently, the invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers

and optionally in the form of the pharmacologically acceptable addition salts thereof, in a concentration of 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of solution.

The above-mentioned topically administered aqueous solutions containing epinastin hydrochloride are preferred according to the invention.

Suitable aqueous solvents are physiologically acceptable aqueous solvents, physiologically acceptable saline solutions being particularly preferred.

According to the invention, topically administered solutions are preferably prepared which typically contain 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, as well as physiological saline solutions as the main carriers. The pH of the solutions according to the invention should preferably be maintained within the range from 6.5 - 7.2 by means of a suitable buffer system. The preparations may also contain conventional, pharmaceutically acceptable excipients, preservatives, stabilisers and/or penetration promoters.

The preferred carrier which may be used in the solutions according to the invention is purified water and preferably a physiological saline solution.

Without restricting the subject matter of the invention to the following, the excipients which may be used according to the invention include viscosity agents such as polyvinyl alcohol, povidone, hydroxypropylmethylcellulose,

poloxamers, carboxymethylcellulose, carbomers and hydroxyethylcellulose.

Without restricting the subject matter of the invention to the following, the preferred preservatives which may be used in the solutions according to the invention include benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

The penetration promoters may be, for example, surfactants, specific organic solvents such as dimethylsulphoxide and other sulphoxides, dimethylacetamide and pyrrolidone, specific amides of heterocyclic amines, glycols such as propyleneglycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof, various cationic, anionic, non-ionogenic and amphoteric surfactants and the like.

Substances may be added as necessary or as desired in order to adjust the tonicity of the solution. Such substances include salts and especially sodium chloride, potassium chloride, mannitol and glycerol or other suitable physiologically acceptable agents for adjusting tonicity, without restricting the invention to the above.

Various buffers and substances may be used to adjust the pH, provided that the preparation obtained is physiologically acceptable. These buffers might include acetate buffer, citrate buffer, phosphate buffer and borate buffer.

Similarly, physiologically acceptable antioxidants which may be used according to the invention include sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene, without restricting the invention to this list.

Other carrier components which may be incorporated in the solutions according to the invention are chelating agents. The preferrred chelating agent is disodium edetate (Na-EDTA), although other chelating agents may also be used instead of or in conjunction with disodium edetate.

The above-mentioned topically administered aqueous solutions according to the invention may be applied either to the conjunctiva or to the nasal mucous membrane. Solutions for ophthalmic use are of equal importance to solutions for nasal application for the purposes of the present invention.

The invention relates not only to the solutions according to the invention mentioned hereinbefore but also to the use of the above-mentioned topically administered aqueous solutions for inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva or the tissue of the nasal mucous membrane.

The present invention also relates to the use of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, for producing the topically administered aqueous solutions according to the invention for treating disorders of the ocular conjunctiva or the nasal mucous membranes in which there is therapeutic value in inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva or the nasal mucous membrane in allergic reactions.

The above-mentioned use for inhibiting LPR is preferred, whilst it is particularly preferable to use the preparation to treat the diseases listed at the beginning.

The Examples shown in Table 1 illustrate the invention without restricting it.

Table 1:	Solution 1 0.05% [g/100ml]	Solution 2 0.01% [g/100ml]	Solution 3 0.05% [g/100mgl]	Solution 4 0.10% [g/100ml]	Solution 5 0.01% [g/100ml]	Solution 6 0.05% [g/100ml]	Solution 7 0.10% [g/100ml]
Epinastin-hydrochloride	0.0500	0.0100	0.0500	0.1000	0.0100	0.0500	0.1000
Na-EDTA	0.0500	0.0500	0.0500	0.0500	-	-	-
Sodium chloride	0.5000	0.5000	0.5000	0.5000	0.5000	0.5000	0.5000
Sodium dihydrogen phosphate dihydrate	0.7800	0.7800	0.7800	0.7800	0.4100	0.4100	0.4100
Benzalkonium chloride	0.0101	0.0101	0.0101	0.0101	0.0101	0.0101	0.0101
Sodium hydroxide	0.0001	0.0001	0.0001	0.0001	-	-	-
Sodium dihydrogen phosphate dihydrate	-	-	-	-	0.6500	0.6500	0.6500
Hydroxyethylcellulose	-	-	-	-	0.1000	0.1000	0.1000
Water	99.4198	99.4598	99.4198	99.3698	99.0749	99.0349	99.9849
	100.8100	100.8100	100.8100	100.8100	100.7550	100.7550	100.7550

CLAIMS:

1. Use of a solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative,

in preparing a medicament for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

2. A use according to claim 1, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

3. A use according to claim 1 or 2, wherein component a) is epinastine hydrochloride.

4. A use according to claim 3, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

5. A use according to claim 3, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

6. A use according to any one of claims 1 to 5, wherein the preservative is selected from the group

consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

7. A use according to any one of claims 1 to 6, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

8. Use of a solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative; and

e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters, antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution,

in preparing a medicament for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

9. A use according to claim 8, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

10. A use according to claim 8 or 9, wherein component a) is epinastine hydrochloride.

11. A use according to claim 10, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

12. A use according to claim 10, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

13. A use according to any one of claims 8 to 12, wherein the preservative is selected from the group consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

14. A use according to any one of claims 8 to 13, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

15. A use according to any one of claims 8 to 14, wherein the viscosity agents are one or more viscosity agents selected from the group consisting of polyvinyl alcohol, povidone, hydroxypropylmethyl cellulose, poloxamers, carboxymethylcellulose, carbomer and hydroxyethyl cellulose.

16. A use according to any one of claims 8 to 15, wherein the penetration promoters are one or more penetration promoters selected from the group consisting of dimethylsulphoxide, dimethylacetamide, pyrrolidone, propyleneglycol, propylene carbonate and oleic acid.

17. A use according to any one of claims 8 to 16, wherein the agents for adjusting tonicity are one or more

agents selected from the group consisting of sodium chloride, potassium chloride, mannitol and glycerol.

18. A use according to any one of claims 8 to 17, wherein the antioxidants are one or more antioxidants selected from the group consisting of sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

19. A use according to any one of claims 8 to 18, wherein the chelating agents are the chelating agent disodium edentate.

20. A use according to any one of claims 9 to 11, wherein b) is water, d) is benzalkonium chloride and e) is sodium chloride, sodium hydrogen phosphate dihydrate and hydroxyethyl cellulose.

21. A use according to any one of claims 9 to 11, wherein b) is water, c) is sodium hydroxide, d) is benzalkonium chloride and e) is sodium chloride, sodium hydrogen phosphate dihydrate, hydroxyethyl cellulose, and sodium-EDTA.

22. Use of a solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative,

for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

23. A use according to claim 22, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

24. A use according to claim 22 or 23, wherein component a) is epinastine hydrochloride.

25. A use according to claim 24, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

26. A use according to claim 24, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

27. A use according to any one of claims 22 to 26, wherein the preservative is selected from the group consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

28. A use according to any one of claims 22 to 27, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

29. Use of a solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative; and

e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters, antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution,

for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

30. A use according to claim 29, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

31. A use according to claim 29 or 30, wherein component a) is epinastine hydrochloride.

32. A use according to claim 31, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

33. A use according to claim 31, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

34. A use according to any one of claims 29 to 33, wherein the preservative is selected from the group consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

35. A use according to any one of claims 29 to 34, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

36. A use according to any one of claims 29 to 35, wherein the viscosity agents are one or more viscosity agents selected from the group consisting of polyvinyl alcohol, povidone, hydroxypropylmethyl cellulose, poloxamers, carboxymethylcellulose, carbomer and hydroxyethyl cellulose.

37. A use according to any one of claims 29 to 36, wherein the penetration promoters are one or more penetration promoters selected from the group consisting of dimethylsulphoxide, dimethylacetamide, pyrrolidone, propyleneglycol, propylene carbonate and oleic acid.

38. A use according to any one of claims 29 to 37, wherein the agents for adjusting tonicity are one or more agents selected from the group consisting of sodium chloride, potassium chloride, mannitol and glycerol.

39. A use according to any one of claims 29 to 38, wherein the antioxidants are one or more antioxidants selected from the group consisting of sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

40. A use according to any one of claims 29 to 39, wherein the chelating agents are the chelating agent disodium edentate.

41. A use according to any one of claims 31 to 33, wherein b) is water, d) is benzalkonium chloride and e) is

sodium chloride, sodium hydrogen phosphate dihydrate and hydroxyethyl cellulose.

42. A use according to any one of claims 31 to 33, wherein b) is water, c) is sodium hydroxide, d) is benzalkonium chloride and e) is sodium chloride, sodium hydrogen phosphate dihydrate, hydroxyethyl cellulose, and sodium-EDTA.

43. A solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative,

for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

44. A solution according to claim 43, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

45. A solution according to claim 43 or 44, wherein component a) is epinastine hydrochloride.

46. A solution according to claim 45, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

47. A solution according to claim 45, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

48. A solution according to any one of claims 43 to 47, wherein the preservative is selected from the group consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

49. A solution according to any one of claims 43 to 48, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

50. A solution consisting of:

a) epinastine, an enantiomer thereof, a racemate of the enantiomers thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.0005 to 0.1 wt.%;

b) water or a physiological saline solution as solvent;

c) a buffer for adjusting the pH to a value from 6.5 to 7.2; and

d) a preservative; and

e) one or more components selected from the group consisting of: chelating agents, viscosity agents penetration promoters, antioxidants, and physiologically acceptable agents for adjusting the tonicity of the solution,

for topical application to conjunctiva or nasal mucosa for treating late phase reaction in allergic rhinitis or conjunctivitis.

51. A solution according to claim 50, wherein the buffer is adjusted to the range of pH from 6.5 to 7.2 by addition of sodium hydroxide.

52. A solution according to claim 50 or 51, wherein component a) is epinastine hydrochloride.

53. A solution according to claim 52, wherein the concentration of epinastine hydrochloride is 0.05 to 0.1 wt.%.

54. A solution according to claim 52, wherein the concentration of epinastine hydrochloride is 0.005 to 0.5 mg/ml.

55. A solution according to any one of claims 50 to 54, wherein the preservative is selected from the group consisting of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.

56. A solution according to any one of claims 50 to 55, wherein the buffer is selected from the group consisting of acetate buffer, citrate buffer, phosphate buffer and borate buffer.

57. A solution according to any one of claims 50 to 56, wherein the viscosity agents are one or more viscosity agents selected from the group consisting of polyvinyl alcohol, povidone, hydroxypropylmethyl cellulose, poloxamers, carboxymethylcellulose, carbomer and hydroxyethyl cellulose.

58. A solution according to any one of claims 50 to 57, wherein the penetration promoters are one or more penetration promoters selected from the group consisting of dimethylsulphoxide, dimethylacetamide, pyrrolidone, propyleneglycol, propylene carbonate and oleic acid.

59. A solution according to any one of claims 50 to 58, wherein the agents for adjusting tonicity are one or more agents selected from the group consisting of sodium chloride, potassium chloride, mannitol and glycerol.

60. A solution according to any one of claims 50 to 59, wherein the antioxidants are one or more antioxidants selected from the group consisting of sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

61. A solution according to any one of claims 50 to 60, wherein the chelating agents are the chelating agent disodium edentate.

62. A solution according to any one of claims 52 to 54, wherein b) is water, d) is benzalkonium chloride and e) is sodium chloride, sodium hydrogen phosphate dihydrate and hydroxyethyl cellulose.

63. A solution according to any one of claims 52 to 54, wherein b) is water, c) is sodium hydroxide, d) is benzalkonium chloride and e) is sodium chloride, sodium hydrogen phosphate dihydrate, hydroxyethyl cellulose, and sodium-EDTA.

FETHERSTONHAUGH & CO.

OTTAWA, CANADA

PATENT AGENTS